A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

INTRODUCTION: This phase I/II study evaluated the safety and anti-tumor effect of the combination of erlotinib with cixutumumab, a recombinant fully humanized anti-insulin-like growth factor-1 receptor IgG1 monoclonal antibody, in advanced non-small cell lung cancer (NSCLC). METHODS: Patients with a...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Weickhardt, Andrew, Doebele, Robert, Oton, Ana, Lettieri, Janice, Maxson, DeLee, Reynolds, Michele, Brown, Amy, Jackson, Mary K., Dy, Grace, Adjei, Araba, Fetterly, Gerald, Lu, Xian, Franklin, Wilbur, Varella-Garcia, Marileila, Hirsch, Fred R., Wynes, Murry W., Youssoufian, Hagop, Adjei, Alex, Camidge, D. Ross
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2012
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3358820/
https://ncbi.nlm.nih.gov/pubmed/22237261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31823c5b11
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια